Advertisement

Topics

FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA

07:07 EDT 5 Jul 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the company’s development candidate SOBI003, a chemically modified human rec...

Other Sources for this Article

Sobi
Media relations
Linda Holmström, Senior Communications Manager
+46 708 734 095
linda.holmstrom@sobi.com
or
Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
+1 347-224-0819, +1 212-579-0506
jorgen.winroth@sobi.com

NEXT ARTICLE

More From BioPortfolio on "FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...